Principal Financial Group Inc. Has $18.89 Million Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Principal Financial Group Inc. increased its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 3.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,009 shares of the medical instruments supplier's stock after purchasing an additional 3,910 shares during the quarter. Principal Financial Group Inc. owned about 0.55% of ICU Medical worth $18,886,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Harvest Fund Management Co. Ltd acquired a new position in ICU Medical during the 4th quarter worth $33,000. Quarry LP lifted its stake in shares of ICU Medical by 764.3% during the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 214 shares during the period. Murphy & Mullick Capital Management Corp acquired a new position in shares of ICU Medical during the fourth quarter valued at $52,000. Russell Investments Group Ltd. boosted its holdings in ICU Medical by 88.8% in the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock valued at $99,000 after acquiring an additional 300 shares during the last quarter. Finally, Sterling Capital Management LLC increased its position in ICU Medical by 813.5% in the fourth quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier's stock worth $105,000 after purchasing an additional 602 shares during the period. Institutional investors and hedge funds own 96.10% of the company's stock.

Insider Buying and Selling

In other ICU Medical news, COO Christian B. Voigtlander sold 4,985 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total transaction of $640,572.50. Following the transaction, the chief operating officer owned 6,088 shares of the company's stock, valued at $782,308. The trade was a 45.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Greenberg sold 1,942 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total value of $278,987.72. Following the completion of the sale, the director directly owned 6,760 shares of the company's stock, valued at approximately $971,141.60. The trade was a 22.32% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,097 shares of company stock worth $4,860,156. Insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

ICUI has been the topic of a number of research reports. KeyCorp cut their target price on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a report on Tuesday, April 8th. Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday, May 18th. Finally, Raymond James Financial dropped their target price on shares of ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating for the company in a research report on Friday, May 9th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $192.67.

ICU Medical Stock Down 1.0%

Shares of ICUI stock traded down $1.31 during trading on Monday, reaching $130.85. The company's stock had a trading volume of 165,661 shares, compared to its average volume of 258,947. ICU Medical, Inc. has a one year low of $117.92 and a one year high of $196.26. The business has a fifty day moving average price of $133.70 and a 200-day moving average price of $144.83. The company has a market cap of $3.22 billion, a price-to-earnings ratio of -34.16 and a beta of 0.87. The company has a quick ratio of 1.52, a current ratio of 2.59 and a debt-to-equity ratio of 0.75.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, topping the consensus estimate of $1.23 by $0.49. ICU Medical had a negative net margin of 3.87% and a positive return on equity of 6.75%. The firm had revenue of $599.49 million for the quarter, compared to analysts' expectations of $574.15 million. During the same period in the previous year, the firm posted $0.96 EPS. The company's revenue for the quarter was up 6.7% on a year-over-year basis. Analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.